<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BD250DEA-56CF-4166-AF0A-87FF46CFE895"><gtr:id>BD250DEA-56CF-4166-AF0A-87FF46CFE895</gtr:id><gtr:firstName>Alistair</gtr:firstName><gtr:surname>Burns</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/81B5FED2-7CEB-4DE2-B12B-9BD129C8F6EC"><gtr:id>81B5FED2-7CEB-4DE2-B12B-9BD129C8F6EC</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Howard</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1641D86F-66D9-4F92-9853-7CEEAD2ADEDD"><gtr:id>1641D86F-66D9-4F92-9853-7CEEAD2ADEDD</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1B55A0B5-9BAC-459E-A15A-668747A93B4D"><gtr:id>1B55A0B5-9BAC-459E-A15A-668747A93B4D</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Tiernan</gtr:otherNames><gtr:surname>O Brien</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CB1C90B9-B007-49CC-A974-2B2E4D6A04DA"><gtr:id>CB1C90B9-B007-49CC-A974-2B2E4D6A04DA</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:surname>Jacoby</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/09EAECD5-3F92-480D-98F8-93B2036394A3"><gtr:id>09EAECD5-3F92-480D-98F8-93B2036394A3</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Bentham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D0EACB96-4227-4884-ACB7-C426E05174B2"><gtr:id>D0EACB96-4227-4884-ACB7-C426E05174B2</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Gerard</gtr:otherNames><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4BFDC368-792E-4AF0-B252-5783E683F4DF"><gtr:id>4BFDC368-792E-4AF0-B252-5783E683F4DF</gtr:id><gtr:firstName>Clive</gtr:firstName><gtr:surname>Ballard</gtr:surname><gtr:orcidId>0000-0003-0022-5632</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/90E1AFC0-E4B9-451F-8D52-80F0D6033F87"><gtr:id>90E1AFC0-E4B9-451F-8D52-80F0D6033F87</gtr:id><gtr:firstName>Edmund</gtr:firstName><gtr:surname>Juszczak</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2436ECEA-E95F-4199-B2B0-45F9F885643C"><gtr:id>2436ECEA-E95F-4199-B2B0-45F9F885643C</gtr:id><gtr:firstName>Clive</gtr:firstName><gtr:surname>Holmes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/71FEAF63-E6E0-4511-B996-5C02C4B0545C"><gtr:id>71FEAF63-E6E0-4511-B996-5C02C4B0545C</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Lindesay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A03F35A5-17CB-4585-A938-BE7B9E93AFAD"><gtr:id>A03F35A5-17CB-4585-A938-BE7B9E93AFAD</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Knapp</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/366D07D0-1FB3-47F1-8F0D-22D2007B3C8A"><gtr:id>366D07D0-1FB3-47F1-8F0D-22D2007B3C8A</gtr:id><gtr:firstName>Roger</gtr:firstName><gtr:surname>Bullock</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0100070"><gtr:id>EC97626A-D391-4D18-BAAC-E222697FFB97</gtr:id><gtr:title>An RCT of a Cholinesterase Inhibitor and Atypical Antipsychotic in the Management of Agitation in Dementia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100070</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1889489</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Alzheimer's Society National Carer's Conference - Warwick</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>A212C525-8F39-4E5D-B4D2-328076889FE7</gtr:id><gtr:impact>The Alzheimer's Society run an annual QRD Conference for their caregivers, Quality Research in Dementia volunteers and other staff. I have delivered updates in emerging drug treatments and the results of the CALM-AD Trial have been very important to them.

Newsletter Website</gtr:impact><gtr:outcomeId>3BBBEEB20DA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>DoH Review of use of antipsychotic drugs in dementia</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>06978E48-C8F2-434D-A900-FB958D2E4EEE</gtr:id><gtr:impact>Cholinesterase inhibitors not regarded as effective alternative treatment</gtr:impact><gtr:outcomeId>3FC5282F163</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Reviews in BMJ, JAGS</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>39BF1278-DE59-4682-A6C4-5A454CEB7E40</gtr:id><gtr:impact>Choinesterase inhibitors no longer seen as potential treatment for agitated behaviour in AD.</gtr:impact><gtr:outcomeId>3F8CB69FDDA</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Technology appraisal</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:guidelineTitle>Technology appraisal dementia drugs</gtr:guidelineTitle><gtr:id>024C3CB3-D47F-4263-9FF2-B1F26AAA8AE6</gtr:id><gtr:impact>Cholinesterase inhibitors known not be to useful for management of behavioural symptoms in dementia</gtr:impact><gtr:outcomeId>91933CE9A8C</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C90B2ECC-1132-4AF2-B7F9-D1FE213CF706</gtr:id><gtr:title>Donepezil for the treatment of agitation in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54b0dbec5169c05d7f8dc0460ddfd3ca"><gtr:id>54b0dbec5169c05d7f8dc0460ddfd3ca</gtr:id><gtr:otherNames>Howard RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>E3A48DA3050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13F0D7DA-FA59-4C27-BEDD-1FE2303BD126</gtr:id><gtr:title>Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).</gtr:title><gtr:parentPublicationTitle>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd3c5db41843229aeb58749cf6517ec0"><gtr:id>fd3c5db41843229aeb58749cf6517ec0</gtr:id><gtr:otherNames>Ballard C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-7481</gtr:issn><gtr:outcomeId>A9795FE1EFC</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100070</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>